Amol Akhade: Medical Oncology at Fortis Hospital. OpenAlex indexes 24 publications with 97 citations (h-index 5).
Data verified 8 Nov 2026
Overview
Updated 12 Nov 2026
Amol Akhade is Medical Oncologist at Fortis Hospital, Mulund. The public record shows 24 publications with 97 citations (h-index 5), centered on Cancer Immunotherapy and Biomarkers, Economic and Financial Impacts of Cancer, Breast Cancer Treatment Studies.
- Most recent indexed publication: 2026 · JCO global oncology
- Top research focus: Cancer Immunotherapy and Biomarkers
Generated from the cited public record · current as of 12 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 2 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 3.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →
Clinical trials
We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 8 Nov 2026
2 congress contributions (2025) across ASCO, ESMO per OpenAlex. The most recent:
- Low-dose anti-PD-(L)1 inhibitor strategies: A systematic review.
ASCO Annual Meeting
ASCO2025Co-author - 2306P Low-dose Anti-PD-(L)1s agents in immune-oncology: Are we prepared?
ESMO Congress
ESMO2025Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 8 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Leveraging Social Media for Oncology Education and Practice: Perspective From Low- and Middle-Income Countries.
JCO global oncology
Article2026 - Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities.
JCO global oncology
Article2023
Most-cited works
by citation count (OpenAlex)- 01Global consequences of the US FDA's accelerated approval of cancer drugsArticle30 citations2022
- 02
- 03
- 04CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?Editorial9 citations2022
- 05Pembrolizumab weight based dosing – A call for policy changeArticle8 citations2022
Network
Updated 8 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Congress posts on X
Post links from an X account tied to this person through reviewed identity evidence.
Listed under ESMO 2026
Listed under ESMO 2026
Listed under ESMO 2026
These links cover selected congress pages. They do not establish attendance or a complete posting history. Post availability may change.
Online presence
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/SuyogCancer
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 8 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MBBS
MD, DM (Medical Oncology)
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dramolakhadecancerdoctor.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- Senior Consultant Medical Oncologist and Hemato-oncologist
Suyog Cancer Clinics and Reliance Hospitals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Media & interviews
press, podcasts and appearances- Speaker at Community Oncology Global Congress (COGC 2026)
OncoDaily: "Amol Akhade at COGC 2026: When Precision Oncology Becomes Precision Confusion"
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Manit Arora
Fortis Hospital
Murali Chakravarthy
Fortis Hospital
Jai Dev Wig
Fortis Hospital
Digambar Behera
Fortis Hospital
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope